摘要
转移性去势抵抗性前列腺癌(metastatic castrate-resistant prostate cancer,mCRPC)是前列腺癌发展的终末阶段。患者生存预后很差。尽管不断地有新的治疗手段出现,比如新型内分泌治疗以及紫杉醇类化疗,mCRPC患者的生存期依然很有限。奥拉帕利是一款聚腺苷酸二磷酸核糖基聚合酶(poly ADP-ribose polymerase,PARP)抑制剂,PARP酶在DNA修复中扮演着重要的角色。奥拉帕利已经获批用于卵巢癌和乳腺癌的治疗。目前,奥拉帕利用于mCRPC治疗的Ⅲ期临床研究PROfound的结果在2019年的欧洲肿瘤内科学会(ESMO)年会与2020年的美国临床肿瘤学会-泌尿生殖系统肿瘤研讨会(ASCO-GU)已经发布。本文将带来PROfound研究的结果以及最新的结果更新。
Metastatic castrate-resistant prostate cancer(mCRPC)is the last stage of prostate cancer.Although new hormonal agents and taxane-based chemotherapies occurred for mCRPC treatment,the overall survival of mCRPC patients is limited.Olaparib is an inhibitor of poly ADP-ribose polymerase(PARP),which has a key role in DNA damage response.It has been approved for ovarian cancer and breast cancer treatment.PROfound,a phase III clinical trial of olaparib in mCRPC treatment,has been reported in 2019 ESMO and 2020 ASCO-GU.In this paper,we will bring the results and updates of PROfound.
作者
黄后宝
HUANG Houbao(Department of Urology,the First Affiliated Hospital of Wannan Medical College,Wuhu 241001,Anhui,China)
出处
《中国临床药理学与治疗学》
CAS
CSCD
2020年第2期144-150,共7页
Chinese Journal of Clinical Pharmacology and Therapeutics
